GGTLC1 and angioedema: Seven (19%) patients had grade 3 or 4 lirilumab-related AEs (asymptomatic increased serum lipase in 2 patients; decreased lymphocyte count, presyncope, increased serum bilirubin, increased gamma-glutamyl transpeptidase levels, abnormal LFT, urticaria plus hypersensitivity, and angioedema in 1 patient each).